Company runs promotional booth on RSV disease awareness during the event at COEX, Seoul.Parents of y...

Company establishes integrated ESG management system by consolidating ESG information from its subsi...

Green light for Phase 1 and 3 trials paves the way for Chinese market entryGlobal Phase 3 trial unde...

Company aims for technology advancement and platform expansion with Korea’s first influenza vaccine ...

Large-scale production facility completed for GBP410, a 21-valent pneumococcal conjugate vaccine can...

Company engages in environmental restoration at Seongnam’s Tancheon WetlandCollaborative ESG action ...

Large-scale production facility completed for GBP410, a 21-valent pneumococcal conjugate vaccine can...

No patent infringement found in exports of individual conjugate bulk substances and research-use fin...

Company strengthens global presence through participation in major international bio events.Company ...

Company aims to develop a bird flu vaccine with rapid mass production and variant responsiveness.SK ...

Commissioner Youngmee Jee of the Korea Disease Control and Prevention Agency and Director General Je...

SK bioscience wins case two years after filing suit challenging global company´s patent monopo...